Precision oncology

Cancer: from mapping to prediction – how to anticipate the disease’s next move

3' min read

Translated by AI
Versione italiana

3' min read

Translated by AI
Versione italiana

At a time when images of war have painfully re-entered our daily lives, using a military metaphor to talk about medicine may seem inappropriate. Yet the distinction between indiscriminate bombing, reconnaissance and precision strikes effectively describes one of the transformations currently taking place in cancer research. With one fundamental difference: the aim is not to destroy, but to save lives.

For decades, many cancer treatments have worked like a carpet bombing: targeting rapidly dividing cancer cells, but also damaging healthy tissue and causing severe side effects. Precision medicine, on the other hand, seeks out specific vulnerabilities in cancer, selectively targeting what only cancer cells need to survive, whilst sparing healthy cells and tissues.

Loading...

The importance of ‘maps’

Genome sequencing and other advances in biotechnology have provided us with a detailed map of the ‘territory’ of cancer. Today, we can observe mutations, chromosomal alterations and changes in gene activity within a tumour. However, knowing the map of an enemy city does not mean knowing which bridges, power stations or logistics hubs are indispensable to its army.

This is where Cancer Dependency Maps come into play. Using technologies such as CRISPR, genes are systematically inactivated in large collections of cancer cells in the laboratory, to identify which ones are essential for their survival. It is like carrying out controlled air strikes to identify the infrastructure which, when taken out of action, causes the greatest damage to the ‘enemy’ tumour. These maps have already revealed numerous weak points and are helping in the search for new therapeutic targets. There is, however, a limitation: we cannot test every possible gene or protein in every tumour.

Taking it one step further with “Precise”

The “Precise” consortium was set up to overcome this barrier. It brings together over 30 European researchers and, with Human Technopole among its founding institutes, aims to transform an atlas of observed vulnerabilities into a system capable of understanding and predicting the patterns underlying them. The scientific paper was published in *Nature Genetics* last August.

In our metaphor, ‘Precise’ adds an intelligence and espionage system to aerial reconnaissance. It integrates data on patients’ tumours, experimental models, genetic manipulations and molecular profiles, using artificial intelligence to link a tumour’s ‘map’ to its weak points. The aim is not merely to map targets but to understand why a vulnerability exists and to predict it even in contexts that have never been observed before.

Whilst a Dependency Map indicates which bridges, if destroyed, would cause the enemy difficulties, Precise aims to identify, based on the layout of other cities, which other bridges and logistical resources are critical and what happens following an attack. An army deprived of a supply route can, in fact, adapt: it can redeploy troops and resources, open up new logistical routes and become dependent on infrastructure that was previously of secondary importance. Similarly, a tumour undergoing treatment can activate alternative mechanisms and become resistant to the treatment. However, this adaptation can create new dependencies and weaknesses. ‘Precise’ aims to predict not only where to target a tumour today, but also which vulnerabilities might emerge in response to the initial treatment.

Identifying the tumour’s weak points

This represents a significant shift in perspective: from cataloguing to prediction, from data to rules, and from maps to intelligence. If these predictions prove to be robust and interpretable, we will be able to speed up the identification of new therapeutic targets, better identify which patients will respond to a new treatment, and design new, more targeted trials.

The promise of ‘Precise’ is simple yet ambitious: not merely to gain a better understanding of cancer, but to learn how to predict its vulnerabilities. AI could thus become an increasingly important tool in precision medicine, helping us to anticipate the tumour’s next moves and stay one step ahead in the battle against the disease.

* Senior Research Group Leader at Human Technopole

Copyright reserved ©
Loading...
Loading...

Brand connect

Loading...

Newsletter

Notizie e approfondimenti sugli avvenimenti politici, economici e finanziari.

Iscriviti